EN3835 for Plantar Fasciitis

Recruiting in Palo Alto (17 mi)

+38 other locations

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Endo Pharmaceuticals

Prior Safety Data

Approved in 1 jurisdiction

Trial Summary

What is the purpose of this trial?This study will assess the efficacy, safety, and tolerability of 2 different doses of EN3835 compared to placebo.

Eligibility Criteria

This trial is for individuals who have had foot pain from plantar fasciitis for at least 6 months and haven't gotten better with common treatments like rest, physical therapy, or pain relievers. Participants should not have other significant foot issues that could interfere with the study.

Inclusion Criteria

I have foot pain from plantar fasciitis.

It seems that the criterion you provided is incomplete. Could you please provide more details or clarify the criterion?

Exclusion Criteria

My BMI is 35 or higher.

Participant Groups

The study is testing two different doses of a medication called EN3835 to see if they are effective and safe compared to a placebo (a treatment without the active drug).

3Treatment groups

Experimental Treatment

Placebo Group

Group I: Group 2: EN3835Experimental Treatment1 Intervention

Participants will receive EN3835 Dose 2.

Group II: Group 1: EN3835Experimental Treatment1 Intervention

Participants will receive EN3835 Dose 1.

Group III: Group 3: PlaceboPlacebo Group1 Intervention

Participants will receive matching placebo.

EN3835 is already approved in United States for the following indications:

🇺🇸 Approved in United States as XIAFLEX for: